Phase 3 STRIVE and ARISE Trials Show Efficacy, Safety for Erenumab in Migraine Prevention – Medscape


Medscape

Phase 3 STRIVE and ARISE Trials Show Efficacy, Safety for Erenumab in Migraine Prevention
Medscape
BOSTON — Treatment with the experimental calcitonin gene-related peptide (CGRP) antibody erenumab (AMG 334, Amgen and Novartis) can reduce the frequency of episodic migraine — without the side effect profile commonly found with other migraine ...
Phase 3 readout keeps Amgen in pole position for CGRP migraine drugFierceBiotech
Novel Biologic Works for Episodic Migraine PreventionMedPage Today
Amgen, Novartis to Co-Commercialize Migr...Genetic Engineering & Biotechnology News
Drug Discovery & Development
all 6 news articles »

Can art imitate migraine? Allergan campaign asks sufferers to visualize symptoms – FiercePharma


FiercePharma

Can art imitate migraine? Allergan campaign asks sufferers to visualize symptoms
FiercePharma
What would a migraine headache look like as art? That's what Allergan is asking sufferers in a new campaign for chronic migraine awareness. Called “Frames of Mind,” the effort asks people coping with migraines to create artwork that visually depicts ...
Press Release: THE MIGRAINE WORLD SUMMIT is Now Live!PRWire (press release)

all 2 news articles »

Phase 3 readout keeps Amgen in pole position for CGRP migraine drug – FierceBiotech


FierceBiotech

Phase 3 readout keeps Amgen in pole position for CGRP migraine drug
FierceBiotech
Amgen has firmed up its lead in the race to bring the first CGRP inhibitor to market for migraine after presenting positive results from its two phase 3 trials. The full set of data from the STRIVE and ARISE studies of erenumab (AMG334)—reported at ...
Amgen, Novartis to Co-Commercialize Migr...Genetic Engineering & Biotechnology News

all 3 news articles »

Help for Migraine Suffers